We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+22.53%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.83B
AUM Growth
+$508M
(+38%)
Cap. Flow
+$309M
Cap. Flow
% of AUM
16.91%
Top 10 Holdings %
Top 10 Hldgs %
53.61%
Holding
96
New
26
Increased
25
Reduced
14
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$52.8M |
| 2 |
CELG
Celgene Corp
CELG
|
+$51.8M |
| 3 |
Biogen
BIIB
|
+$47.2M |
| 4 |
Pacira BioSciences
PCRX
|
+$41.8M |
| 5 |
Burlington
BURL
|
+$32.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$73.6M |
| 2 |
SGI
Somnigroup International
SGI
|
+$34.1M |
| 3 |
SRCL
Stericycle Inc
SRCL
|
+$31.5M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$26.1M |
| 5 |
PGNX
Progenics Pharmaceuticals Inc
PGNX
|
+$23.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.87% |
| 2 | Consumer Discretionary | 11.8% |
| 3 | Consumer Staples | 6.82% |
| 4 | Industrials | 4.98% |
| 5 | Communication Services | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VLRX
51
DELISTED
VALERITAS HOLDINGS INC
VLRX
| $6.49M | 0.36% |
995,000
+2,500
| +0.3% | +$20.2K |
|
|
RNTX
52
Rein Therapeutics
RNTX
$63.1M
| $6.31M | 0.35% |
+161,692
| New | +$5.04M |
|
53
Larimar Therapeutics
LRMR
$397M
| $5.78M | 0.32% |
175,667
+70,834
| +68% | +$3.63M |
|
54
Spotify
SPOT
$103B
| $5.55M | 0.3% |
+40,000
| New | +$5.47M |
|
55
Dropbox
DBX
$7.6B
| $5.45M | 0.3% |
+250,000
| New | +$5.82M |
|
56
Kiora Pharmaceuticals
KPRX
$11.3M
| $5.43M | 0.3% |
3,299
+102
| +3% | +$248K |
|
|
PETQ
57
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $4.96M | 0.27% |
+158,000
| New | +$4.46M |
|
|
FPRX
58
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $4.02M | 0.22% |
+300,000
| New | +$3.42M |
|
59
Tyson Foods
TSN
$20.4B
| $3.61M | 0.2% |
+52,000
| New | +$3.22M |
|
60
AYTU BioPharma
AYTU
$23.9M
| $3.34M | 0.18% |
10,000
+9,500
| +1,900% | +$2.37M |
|
61
Ovid Therapeutics
OVID
$414M
| $3.15M | 0.17% |
1,780,000
+180,000
| +11% | +$450K |
|
62
CRISPR Therapeutics
CRSP
$4.73B
| $2.86M | 0.16% |
80,000
-92,000
| -53% | -$3.18M |
|
|
SRRA
63
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $2.67M | 0.15% |
39,000
-1,000
| -3% | -$64.2K |
|
|
MDGSW
64
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
| $2.04M | 0.11% |
1,285,715
| – | – |
|
|
BLPH
65
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $1.89M | 0.1% |
+193,333
| New | +$2.13M |
|
|
DYNT
66
DELISTED
Dynatronics Corp
DYNT
| $1.19M | 0.07% |
115,200
+3,000
| +3% | +$35.3K |
|
|
ROX
67
DELISTED
Castle Brands, Inc.
ROX
| $697K | 0.04% |
1,000,000
-42,000
| -4% | -$35K |
|
68
Cenntro
CENN
$7.89M
| $460K | 0.03% |
2
-2
| -50% | -$1.02M |
|
69
Moleculin Biotech
MBRX
$2.83M
| $179K | 0.01% |
+98
| New | +$292K |
|
70
Advance Auto Parts
AAP
$3.35B
| – | – |
-42,000
| Closed | -$6.61M |
|
71
Achieve Life Sciences
ACHV
$659M
| – | – |
-22,400
| Closed | -$542K |
|
|
ASRT
72
DELISTED
Assertio
ASRT
| – | – |
-54,633
| Closed | -$11.8M |
|
73
Alphatec Holdings
ATEC
$1.46B
| – | – |
-3,338,414
| Closed | -$7.64M |
|
74
Citius Pharmaceuticals
CTXR
$15.6M
| – | – |
-29,537
| Closed | -$768K |
|
75
CVS Health
CVS
$133B
| – | – |
-158,000
| Closed | -$9.75M |
|
Similar funds
CRC
RMDI
F
DCP
EW
O
PA
DSC
Armistice Capital's Q1 2019 Portfolio in Review
As of Q1 2019, Armistice Capital held 96 positions worth $1.83B, up 38% from $1.32B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Armistice Capital deployed $309M of net new capital in Q1 2019, opening 26 new positions and adding to 25 existing holdings. Its largest new stake was Madrigal Pharmaceuticals: 425,000 shares worth $53.2M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Clovis Oncology, Inc., an estimated $73.6M trimmed.
- Armistice Capital's largest Q1 2019 buy was Madrigal Pharmaceuticals: 425,000 shares worth $53.2M.
- Armistice Capital added most to Target in Q1 2019, an estimated $21.9M increase.
- Armistice Capital's biggest Q1 2019 reduction was Clovis Oncology, Inc., cutting an estimated $73.6M.
- Armistice Capital fully exited Somnigroup International in Q1 2019, selling an estimated $34.1M.
- Armistice Capital's ten largest holdings make up 54% of its $1.83B portfolio in Q1 2019.
- Armistice Capital opened 26 new positions and closed 27 in Q1 2019.
- Armistice Capital's portfolio value rose 38% quarter-over-quarter to $1.83B.
Based on Armistice Capital's 13F filing for Q1 2019, filed 15 May 2019.